148 related articles for article (PubMed ID: 23588637)
21. Elevated levels of telomerase activity in malignant pheochromocytoma.
Kubota Y; Nakada T; Sasagawa I; Yanai H; Itoh K
Cancer; 1998 Jan; 82(1):176-9. PubMed ID: 9428495
[TBL] [Abstract][Full Text] [Related]
22. [Malignant pheochromocytoma. A case report and comments on a rare pathology].
Boneschi M; Erba M; Rinaldi P; Cusmai F; Miani S
Minerva Chir; 1999; 54(1-2):73-8. PubMed ID: 10230231
[TBL] [Abstract][Full Text] [Related]
23. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
25. Development of differential diagnosis for benign and malignant pheochromocytomas.
Gao B; Kong F; Xu Z
Int J Urol; 2008 Sep; 15(9):771-7. PubMed ID: 18651863
[TBL] [Abstract][Full Text] [Related]
26. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma.
Sangoi AR; McKenney JK
Am J Surg Pathol; 2010 Mar; 34(3):423-32. PubMed ID: 20154585
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute.
Huang KH; Chung SD; Chen SC; Chueh SC; Pu YS; Lai MK; Lin WC
Int J Urol; 2007 Mar; 14(3):181-5. PubMed ID: 17430251
[TBL] [Abstract][Full Text] [Related]
28. [Personal experience in diagnosis and localization of pheochromocytoma].
Andjelković Z; Tavcar I
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():14-9. PubMed ID: 12584992
[TBL] [Abstract][Full Text] [Related]
29. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population.
Zöller ME; Rembeck B; Odén A; Samuelsson M; Angervall L
Cancer; 1997 Jun; 79(11):2125-31. PubMed ID: 9179058
[TBL] [Abstract][Full Text] [Related]
30. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients.
Saeger W; Fassnacht M; Chita R; Prager G; Nies C; Lorenz K; Bärlehner E; Simon D; Niederle B; Beuschlein F; Allolio B; Reincke M
Hum Pathol; 2003 Feb; 34(2):180-6. PubMed ID: 12612887
[TBL] [Abstract][Full Text] [Related]
31. [About the signs of malignant pheochromocytoma].
Simonenko VB; Makanin MA; Dulin PA; Vasilchenko MI; Lesovik VS
Klin Med (Mosk); 2012; 90(10):64-8. PubMed ID: 23285767
[TBL] [Abstract][Full Text] [Related]
32. Utility of chemical shift and diffusion-weighted imaging in characterization of hyperattenuating adrenal lesions at 3.0T.
Song J; Zhang C; Liu Q; Yu T; Jiang X; Xia Q; Zhang Y; Sequeiros RB
Eur J Radiol; 2012 Sep; 81(9):2137-43. PubMed ID: 22036592
[TBL] [Abstract][Full Text] [Related]
33. Oncologic aspects of pheochromocytoma: the importance of follow-up.
Scott HW; Halter SA
Surgery; 1984 Dec; 96(6):1061-6. PubMed ID: 6505959
[TBL] [Abstract][Full Text] [Related]
34. Pheochromocytoma in Dogs Undergoing Adrenalectomy.
Zini E; Nolli S; Ferri F; Massari F; Gerardi G; Nicoli S; Romanelli G; Montinaro V; Trez D; Cavicchioli L; Ferro S
Vet Pathol; 2019 May; 56(3):358-368. PubMed ID: 30595108
[TBL] [Abstract][Full Text] [Related]
35. [Malignant pheochromocytoma: diagnosis and treatment].
Yang D; Li S; Li X; Liu S; Wang H; Han W; Hao J
Zhonghua Wai Ke Za Zhi; 1999 Feb; 37(2):104-5. PubMed ID: 11829794
[TBL] [Abstract][Full Text] [Related]
36. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas.
Unger P; Hoffman K; Pertsemlidis D; Thung S; Wolfe D; Kaneko M
Arch Pathol Lab Med; 1991 May; 115(5):484-7. PubMed ID: 1673596
[TBL] [Abstract][Full Text] [Related]
37. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
[TBL] [Abstract][Full Text] [Related]
38. Expression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytoma.
Xu Y; Qi Y; Rui W; Zhu Y; Zhang C; Zhao J; Wei Q; Wu Y; Shen Z; Ning G
J Clin Pathol; 2013 Apr; 66(4):286-90. PubMed ID: 23322822
[TBL] [Abstract][Full Text] [Related]
39. [Recurrent pheochromocytoma].
Sun Z; Wang Y; Li Z
Zhonghua Wai Ke Za Zhi; 1998 Jan; 36(1):59-60. PubMed ID: 11715546
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic management of benign and malignant pheochromocytoma.
Scholz T; Schulz C; Klose S; Lehnert H
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):155-9. PubMed ID: 17427102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
